X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (16073) 16073
Book Review (1167) 1167
Publication (924) 924
Book Chapter (19) 19
Magazine Article (14) 14
Conference Proceeding (12) 12
Dissertation (9) 9
Book / eBook (7) 7
Newsletter (4) 4
Data Set (3) 3
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (15116) 15116
animals (8758) 8758
male (8731) 8731
humans (8629) 8629
imidazoles - pharmacology (7110) 7110
female (5905) 5905
imidazoles - administration & dosage (5457) 5457
imidazoles - therapeutic use (4199) 4199
rats (4107) 4107
middle aged (3068) 3068
adult (2658) 2658
pharmacology & pharmacy (2433) 2433
mice (2423) 2423
aged (2350) 2350
dose-response relationship, drug (1956) 1956
imidazoles - adverse effects (1941) 1941
oncology (1595) 1595
time factors (1450) 1450
treatment outcome (1335) 1335
abridged index medicus (1332) 1332
blood pressure - drug effects (1330) 1330
rats, sprague-dawley (1295) 1295
pyridines - pharmacology (1265) 1265
administration, oral (1229) 1229
zoledronic acid (1032) 1032
analysis (976) 976
diphosphonates - administration & dosage (972) 972
imidazoles - pharmacokinetics (954) 954
cancer (946) 946
diphosphonates - therapeutic use (884) 884
dogs (872) 872
rats, wistar (859) 859
disease models, animal (857) 857
imidazoles - chemistry (821) 821
research (816) 816
double-blind method (783) 783
drug therapy, combination (766) 766
neurosciences (755) 755
tetrazoles - pharmacology (753) 753
cell line, tumor (750) 750
apoptosis (721) 721
heart rate - drug effects (712) 712
care and treatment (708) 708
drug therapy (690) 690
enzyme inhibitors - pharmacology (678) 678
adolescent (676) 676
bisphosphonates (668) 668
biochemistry & molecular biology (665) 665
expression (664) 664
aged, 80 and over (653) 653
losartan (649) 649
drug administration schedule (648) 648
therapy (633) 633
hypertension - drug therapy (627) 627
medicine & public health (616) 616
endocrinology & metabolism (615) 615
imidazoles (614) 614
hypertension (610) 610
bone density conservation agents - administration & dosage (603) 603
imidazoles - metabolism (596) 596
health aspects (592) 592
diphosphonates - adverse effects (591) 591
bone density conservation agents - therapeutic use (590) 590
in-vitro (587) 587
in vitro techniques (585) 585
veterinary sciences (583) 583
inhibition (573) 573
angiotensin receptor antagonists (564) 564
cells, cultured (559) 559
clinical trials as topic (545) 545
rabbits (536) 536
imidazoles - toxicity (535) 535
mice, inbred c57bl (534) 534
apoptosis - drug effects (530) 530
diphosphonates - pharmacology (528) 528
rodents (528) 528
peripheral vascular disease (527) 527
antihypertensive agents - pharmacology (526) 526
injections, intravenous (525) 525
double-blind (515) 515
cell biology (512) 512
cells (505) 505
hemodynamics - drug effects (503) 503
article (502) 502
osteoporosis (490) 490
bone neoplasms - secondary (487) 487
toxicology (483) 483
drugs (477) 477
physiology (477) 477
administration, topical (476) 476
activation (475) 475
rats, inbred strains (473) 473
rat (471) 471
chemistry, medicinal (466) 466
pharmacology (466) 466
proteins (466) 466
pharmacokinetics (462) 462
efficacy (461) 461
drug interactions (447) 447
medetomidine (440) 440
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (15144) 15144
German (301) 301
Japanese (168) 168
Russian (134) 134
French (118) 118
Italian (53) 53
Spanish (52) 52
Chinese (34) 34
Polish (21) 21
Dutch (15) 15
Hungarian (14) 14
Danish (11) 11
Portuguese (9) 9
Czech (8) 8
Bulgarian (7) 7
Swedish (7) 7
Norwegian (4) 4
Croatian (2) 2
Hebrew (2) 2
Lithuanian (2) 2
Romanian (2) 2
Serbian (2) 2
Slovak (2) 2
Turkish (2) 2
Finnish (1) 1
Korean (1) 1
Ukrainian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1389 - 1398
Summary Background In the COMBI-v trial, patients with previously untreated BRAF Val600Glu or Val600Lys mutant unresectable or metastatic melanoma who were... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EQ-5D | QUESTIONNAIRE QLQ-C30 | ONCOLOGY | SCORES | RELIABILITY | EUROPEAN-ORGANIZATION | CANCER | VALIDITY | Prospective Studies | Skin Neoplasms - drug therapy | Oximes - adverse effects | Humans | Oximes - administration & dosage | Protein Kinase Inhibitors - adverse effects | Indoles - administration & dosage | Time Factors | DNA Mutational Analysis | Imidazoles - therapeutic use | MAP Kinase Kinase Kinases - antagonists & inhibitors | Genetic Predisposition to Disease | Administration, Oral | Imidazoles - adverse effects | Pyrimidinones - adverse effects | Pyrimidinones - therapeutic use | Risk Factors | MAP Kinase Kinase Kinases - metabolism | Disease Progression | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Protein Kinase Inhibitors - administration & dosage | Phenotype | Indoles - adverse effects | Intention to Treat Analysis | Quality of Life | Indoles - therapeutic use | Biomarkers, Tumor - genetics | Pyrimidinones - administration & dosage | Mutation | Sulfonamides - administration & dosage | Melanoma - mortality | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Imidazoles - administration & dosage | Oximes - therapeutic use | Pyridones - administration & dosage | Melanoma - genetics | Skin Neoplasms - mortality | Surveys and Questionnaires | Skin Neoplasms - pathology | Drug Administration Schedule | Treatment Outcome | Melanoma - secondary | Disease-Free Survival | Sulfonamides - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Skin Neoplasms - genetics | Sulfonamides - adverse effects | Pyridones - therapeutic use | Pyridones - adverse effects | Care and treatment | Hospitals | Metastasis | Gene mutations | Comparative analysis | Index Medicus
Journal Article
Annals of Oncology, ISSN 0923-7534, 02/2015, Volume 26, Issue 2, pp. 313 - 320
Journal Article
PLoS ONE, ISSN 1932-6203, 02/2016, Volume 11, Issue 2, pp. e0148984 - e0148984
The induction of high levels of systemic and mucosal humoral immunity is a key goal for many prophylactic vaccines. However, adjuvant strategies developed in... 
PATHWAYS | IMMUNIZATION | RESPONSES | DENDRITIC CELLS | PROTECTION | MACROPHAGES | MULTIDISCIPLINARY SCIENCES | MUCOSAL | LIGAND | SECRETION | EXPRESSION | HIV Antibodies - blood | Antibody Specificity | Adjuvants, Immunologic - administration & dosage | Immunoglobulin G - blood | Toll-Like Receptor 8 - administration & dosage | Lipid A - analogs & derivatives | AIDS Vaccines - immunology | Immunity, Mucosal - drug effects | Toll-Like Receptor 8 - immunology | 1,2-Dipalmitoylphosphatidylcholine - administration & dosage | Immunoglobulin G - biosynthesis | Swine | HIV Antibodies - biosynthesis | Toll-Like Receptor 4 - agonists | Models, Animal | Lipid A - administration & dosage | Antibody Affinity | Toll-Like Receptor 4 - immunology | Lipid A - pharmacology | Toll-Like Receptor 7 - administration & dosage | 1,2-Dipalmitoylphosphatidylcholine - pharmacology | AIDS Vaccines - administration & dosage | Adjuvants, Immunologic - pharmacology | Dose-Response Relationship, Immunologic | env Gene Products, Human Immunodeficiency Virus - immunology | Vagina - immunology | Imidazoles - administration & dosage | Neutralization Tests | Toll-Like Receptor 4 - administration & dosage | Antigens - administration & dosage | Immunization, Secondary | Vaccination - methods | HIV Antibodies - immunology | Immunoglobulin G - immunology | Toll-Like Receptor 7 - immunology | Swine, Miniature | Female | Injections, Intradermal | Toll-Like Receptor 8 - agonists | Toll-Like Receptor 7 - agonists | Immunity, Innate | Organ Specificity | Administration, Intranasal | Animals | Nasal Mucosa - immunology | env Gene Products, Human Immunodeficiency Virus - administration & dosage | Antigens - immunology | Imidazoles - antagonists & inhibitors | Drug Combinations | Physiological aspects | Toll-like receptors | Genetic aspects | Immune response | Research | Animal models | Mucosal immunity | Mucosa | Immunoglobulin G | Infections | Vaccines | Immunity | Proteins | Signal transduction | Inoculation | Immunology | Pathways | Rodents | Human immunodeficiency virus--HIV | Immunity (humoral) | Antigens | Medical research | TLR7 protein | Vagina | Priming | Glycoproteins | TLR4 protein | Gene expression | Immune response (humoral) | Immune systems | Medicine | Signaling | Infectious diseases | Ligands | Index Medicus | HIV | Human immunodeficiency virus
Journal Article
Journal of Internal Medicine, ISSN 0954-6820, 06/2015, Volume 277, Issue 6, pp. 690 - 706
There is an increasing number of effective therapies for fracture prevention in adults at risk of osteoporosis. However, shortcomings in the evidence... 
calcium | vitamin D | strontium | bisphosphonate | SERM | osteoporosis | denosumab | Strontium | Osteoporosis | Bisphosphonate | Calcium | Vitamin D | Denosumab | BONE-MINERAL DENSITY | ORAL BISPHOSPHONATES | VITAMIN-D-RECEPTOR | ELDERLY-WOMEN | RANDOMIZED CONTROLLED-TRIAL | ZOLEDRONIC ACID | CALCIUM SUPPLEMENTATION | MEDICINE, GENERAL & INTERNAL | CLINICAL-TRIALS | PLACEBO-CONTROLLED TRIAL | HEALTHY POSTMENOPAUSAL WOMEN | Etidronic Acid - administration & dosage | Bone Density Conservation Agents - adverse effects | Osteoporosis - prevention & control | Risk Assessment | Teriparatide - administration & dosage | Humans | Osteoporotic Fractures - prevention & control | Imidazoles - administration & dosage | Treatment Outcome | Diphosphonates - administration & dosage | Thiophenes - administration & dosage | Bone Density Conservation Agents - administration & dosage | Evidence-Based Medicine | Calcium Compounds - administration & dosage | Spinal Fractures - prevention & control | Antibodies, Monoclonal, Humanized - administration & dosage | Raloxifene Hydrochloride - administration & dosage | Hip Fractures - prevention & control | Vitamin D - administration & dosage | Risedronate Sodium | Diphosphonates - adverse effects | Etidronic Acid - analogs & derivatives | Alendronate - administration & dosage | Prevention | Calcifediol | Alfacalcidol | Analysis | Index Medicus
Journal Article
Lancet Oncology, The, ISSN 1470-2045, 2008, Volume 9, Issue 9, pp. 840 - 849
Journal Article
Cancer, ISSN 0008-543X, 02/2016, Volume 122, Issue 3, pp. 411 - 419
Toxicities associated with vascular endothelial growth factor–targeted therapies can often compromise clinical benefit in patients with metastatic renal cell... 
International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) | toxicity | renal cell carcinoma | risk factors | treatment discontinuation | model | VEGF‐targeted therapies | VEGF-targeted therapies | SAFETY | OLDER-ADULTS | PHASE-III | SORAFENIB | CANCER | INTERFERON-ALPHA | ANGIOGENESIS INHIBITOR THERAPIES | ONCOLOGY | TREATMENT PATTERNS | SUNITINIB | CLINICAL-PRACTICE | Predictive Value of Tests | Humans | Middle Aged | Male | Fatigue - chemically induced | Kidney Neoplasms - metabolism | Antineoplastic Agents - administration & dosage | Hand-Foot Syndrome - etiology | Indazoles - administration & dosage | Indoles - administration & dosage | Kidney Neoplasms - blood | Pyrroles - administration & dosage | Aged, 80 and over | Pyrroles - adverse effects | Bevacizumab - administration & dosage | Risk Assessment | Imidazoles - adverse effects | Risk Factors | Niacinamide - adverse effects | Mucositis - chemically induced | Carcinoma, Renal Cell - metabolism | Indoles - adverse effects | Indazoles - adverse effects | Sulfonamides - administration & dosage | Niacinamide - analogs & derivatives | Bevacizumab - adverse effects | Imidazoles - administration & dosage | Diarrhea - chemically induced | Antineoplastic Agents - adverse effects | Phenylurea Compounds - adverse effects | Female | Retrospective Studies | Vascular Endothelial Growth Factor A - drug effects | Carcinoma, Renal Cell - drug therapy | Molecular Targeted Therapy - methods | Databases, Factual | Molecular Targeted Therapy - adverse effects | Carcinoma, Renal Cell - blood | Drug Administration Schedule | Pyrimidines - administration & dosage | Kaplan-Meier Estimate | Models, Statistical | Niacinamide - administration & dosage | Phenylurea Compounds - administration & dosage | Carcinoma, Renal Cell - secondary | Pyrimidines - adverse effects | Sulfonamides - adverse effects | Kidney Neoplasms - pathology | Aged | Kidney Neoplasms - drug therapy | Care and treatment | Dosage and administration | Carcinoma, Renal cell | Diagnosis | Vascular endothelial growth factor | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9829, pp. 1893 - 1901
Summary Background Dabrafenib is an inhibitor of BRAF kinase that is selective for mutant BRAF. We aimed to assess its safety and tolerability and to establish... 
Internal Medicine | SURVIVAL | IRRADIATION | MEDICINE, GENERAL & INTERNAL | PATHWAY | RAF INHIBITOR RESISTANCE | B-RAF | MUTATIONS | CANCER | BRAF(V600E) | VEMURAFENIB | Oximes - adverse effects | Humans | Middle Aged | Carcinoma, Squamous Cell - chemically induced | Oximes - administration & dosage | Imidazoles - administration & dosage | Male | Fatigue - chemically induced | Antineoplastic Agents - administration & dosage | Fever - chemically induced | Indoles - administration & dosage | Brain Neoplasms - secondary | Neoplasms - genetics | Antineoplastic Agents - adverse effects | Melanoma - genetics | Adult | Female | Drug Administration Schedule | Imidazoles - adverse effects | Genotype | Treatment Outcome | Skin Neoplasms - chemically induced | Brain Neoplasms - drug therapy | Mutation - genetics | Melanoma - secondary | Neoplasms - drug therapy | Proto-Oncogene Proteins B-raf - antagonists & inhibitors | Maximum Tolerated Dose | Indoles - adverse effects | Proto-Oncogene Proteins B-raf - genetics | Melanoma - drug therapy | Sulfonamides - adverse effects | Sulfonamides - administration & dosage | Antimitotic agents | Complications and side effects | Melanoma | Dosage and administration | Metastasis | Antineoplastic agents | Drug therapy | Clinical trials | Medical research | Chemotherapy | Mutation | Toxicity | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
Journal of Controlled Release, ISSN 0168-3659, 03/2012, Volume 158, Issue 3, pp. 470 - 478
Journal Article